GlassScriptPhysician profile
Sagar Panse
NPI 1033132212
$541,865.08
in general payments reported to CMS, 2019-2025
40 companies · $2,445 in 2025
The $2,445 reported for 2025 was more than what 91% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $151K · 2020: $40K · 2021: $95K · 2022: $160K · 2023: $59K · 2024: $34K · 2025: $2,445.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $73K · Travel and Lodging: $12K · Food and Beverage: $5,465 · Consulting Fee: $4,800 · Education: $163.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $73,000.00 |
| Travel and Lodging | $11,676.33 |
| Food and Beverage | $5,465.43 |
| Consulting Fee | $4,800.00 |
| Education | $162.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $174,218.10 | 2019-2025 | Farxiga, Lokelma |
| Bayer Healthcare Pharmaceuticals INC. | $154,471.59 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $149,140.49 | 2019-2022 | |
| Vifor Pharma, INC. | $46,223.75 | 2019-2025 | Veltassa, Korsuva |
| Janssen Scientific Affairs, LLC | $5,818.31 | 2019 | |
| Horizon Therapeutics Plc | $5,116.49 | 2019-2023 | Krystexxa |
| Scpharmaceuticals INC. | $3,248.41 | 2023-2025 | |
| Aurinia Pharma U.S., INC. | $455.27 | 2021-2025 | Lupkynis |
| Otsuka America Pharmaceutical, INC. | $408.15 | 2019-2025 | Jynarque |
| Novo Nordisk INC | $372.51 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $338.08 | 2019-2025 | Krystexxa, Tavneos |
| Akebia Therapeutics INC | $270.35 | 2020-2025 | Vafseo, Auryxia |
| Travere Therapeutics, INC. | $256.95 | 2022-2025 | Filspari |
| Valeritas, INC. | $196.95 | 2019 | |
| Novartis Pharmaceuticals Corporation | $180.62 | 2023-2025 |
Show all 39 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sagar Panse listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.